Dr. Aru Narendran, MD., PhD. - University of Calgary

Dr. Aru Narendran

MD., PhD.

University of Calgary

Canada

Main Specialties: Oncology

Additional Specialties: Pediatric Oncology

Dr. Aru Narendran, MD., PhD. - University of Calgary

Dr. Aru Narendran

MD., PhD.

Introduction

Primary Affiliation: University of Calgary - Canada

Specialties:

Additional Specialties:

Metrics

Number of Publications

52

Publications

Number of Profile Views

546

Profile Views

Number of Article Reads

880

Reads

Number of PubMed Central Citations

839

PubMed Central Citations

Top co-authors

Aarthi Jayanthan
Aarthi Jayanthan

Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory for Pre-Clinical and Drug Discovery Studies

19
Anjali Singh
Anjali Singh

Banaras Hindu University

8
Yibing Ruan
Yibing Ruan

Department of Cancer Epidemiology and Prevention Research

7
Lia Gore
Lia Gore

University of Colorado Cancer Center

5
Melani Sooriyaarachchi
Melani Sooriyaarachchi

University of Calgary

5
Jessica Boklan
Jessica Boklan

University of Arizona

4
Melvin H Freedman
Melvin H Freedman

University of Toronto

4
James A Whitlock
James A Whitlock

Vanderbilt University Medical Center

4
Xueqing Lun
Xueqing Lun

Southern Alberta Cancer Research Institute

4

Publications

52Publications

880Reads

839PubMed Central Citations

In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies.

Curr Cancer Drug Targets 2017 ;17(6):569-584

Departments of Pediatrics and Oncology, University of Calgary and Alberta Children's Hospital, Calgary, Alberta, Canada.

View Article
May 2018
8 Reads
3.52 Impact Factor

Tuning the metabolism of the anticancer drug cisplatin with chemoprotective agents to improve its safety and efficacy.

Metallomics 2016 11;8(11):1170-1176

Department of Chemistry, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada.

View Article
November 2016
13 Reads
2 PubMed Central Citations(source)
3.58 Impact Factor

Response to "Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?".

Neuro Oncol 2016 Jan;18(1):143-4

Division of Pediatric Oncology, Alberta Children's Hospital and POETIC Laboratory for Preclinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada.

View Article
January 2016
10 Reads
1 PubMed Central Citation(source)
5.56 Impact Factor

Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells.

J Exp Clin Cancer Res 2015 Sep 18;34:104. Epub 2015 Sep 18.

POETIC Laboratory for Preclinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada.

View Article
September 2015
22 Reads
2 PubMed Central Citations(source)

In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.

Neuro Oncol 2015 Aug 20;17(8):1086-94. Epub 2015 Jan 20.

Southern Alberta Cancer Research Institute, University of Calgary, Calgary, Canada (B.A.M., F.J.Z., A.N., X.L, E.U.K, P.A.F.); Department of Pediatrics, University of Calgary, Calgary, Canada (A.N.); Department of Oncology, University of Calgary, Calgary, Canada (A.N., P.A.F.); Department of Physiology & Pharmacology, University of Calgary, Calgary, Canada (E.U.K.); Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida (A.P., R.S.K, P.A.F.); Department of Molecular Genetics & Microbiology, University of Florida, Gainesville, Florida (G.M.).

View Article
August 2015
12 Reads
8 PubMed Central Citations(source)
5.56 Impact Factor

Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Neuro Oncol 2015 Jun 12;17(6):822-31. Epub 2014 Nov 12.

Division of Pediatric Oncology, Alberta Children's Hospital and POETIC Laboratory for Preclinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada (Y.R., A.J., X.L., R.A., A.N.); Department of Biological Sciences, University of Lethbridge, Lethbridge, Canada (A.K., O.K.); Department of Pathology, Yokohama City University School of Medicine and Division of Diagnostic Pathology, Tokyo Women's Medical University Hospital, Tokyo, Japan (Y.N.); Department of Pathology and Laboratory Medicine, Alberta Children's Hospital and Calgary Laboratory Services, Calgary, Canada (J.R.W., A.P.); Department of Neurology, Alberta Children's Hospital, Calgary, Canada (A.K.).

View Article
June 2015
22 Reads
5 PubMed Central Citations(source)
5.56 Impact Factor

Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents.

PLoS One 2014 21;9(7):e102741. Epub 2014 Jul 21.

Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory for Pre-Clinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada; Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.

View Article
April 2015
8 Reads
1 PubMed Central Citation(source)
3.23 Impact Factor

Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro.

Metallomics 2014 Nov;6(11):2034-41

Department of Chemistry, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada.

View Article
November 2014
11 Reads
5 PubMed Central Citations(source)
3.58 Impact Factor

Chemoprotection by D-methionine against cisplatin-induced side-effects: insight from in vitro studies using human plasma.

Metallomics 2014 Mar 16;6(3):532-41. Epub 2013 Dec 16.

Department of Chemistry, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada.

View Article
March 2014
15 Reads
2 PubMed Central Citations(source)
3.58 Impact Factor

Survivin as a preferential target for cancer therapy.

Int J Mol Sci 2014 Feb 13;15(2):2494-516. Epub 2014 Feb 13.

Department of Biochemistry & Molecular Biology, Faculty of Medicine, University of Calgary, 3330 Hospital Dr. NW., Calgary, AB T2N 4N1, Canada.

View Article
February 2014
11 Reads
47 PubMed Central Citations(source)
2.86 Impact Factor

A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes.

Neuro Oncol 2014 Jan 4;16(1):62-71. Epub 2013 Dec 4.

Corresponding authors: Jennifer A. Chan, MD, Department of Pathology & Laboratory Medicine, University of Calgary, HRIC 2A25, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1. Annie Huang, MD, PhD, Division of Hematology-Oncology, Department of Pediatrics, The Hospital for Sick Children, TMDT, 11-401P, 101 College St., Toronto, Ontario, Canada M5G 1L7

View Article
January 2014
33 Reads
14 PubMed Central Citations(source)
5.56 Impact Factor

Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.

Cancer Res 2013 Nov 9;73(22):6734-44. Epub 2013 Sep 9.

Authors' Affiliations: Department of Pediatrics; Division of Anatomic Pathology, Department of Pathology and Laboratory Medicine; Division of Pediatric Neurosurgery, Department of Surgery, BC Children's Hospital, University of British Columbia; Department of Pathology and Laboratory Medicine, Centre for Applied Genomics, British Columbia Cancer Agency, Vancouver, British Columbia; Division of Neurosurgery, Department of Surgery, Faculty of Health Sciences, McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton; The Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, Toronto, Ontario; Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory for Pre-Clinical and Drug Discovery Studies, Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada; and Division of Pediatric Neuro-Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article
November 2013
25 Reads
27 PubMed Central Citations(source)
9.33 Impact Factor

Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors.

Mol Oncol 2013 Oct 14;7(5):944-54. Epub 2013 Jun 14.

Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory for Pre-Clinical and Drug Discovery Studies, University of Calgary, Canada and Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.

View Article
October 2013
41 Reads
12 PubMed Central Citations(source)
5.33 Impact Factor

Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.

Leuk Lymphoma 2013 Jul 29;54(7):1505-16. Epub 2012 Dec 29.

Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory for Pre-Clinical and Drug Discovery Studies, University of Calgary, Calgary, AB, Canada.

View Article
July 2013
13 Reads
6 PubMed Central Citations(source)

A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.

Clin Cancer Res 2013 Jul 9;19(13):3649-58. Epub 2013 May 9.

The Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO 80045, USA.

View Article
July 2013
36 Reads
8 PubMed Central Citations(source)
8.72 Impact Factor

Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.

Mol Oncol 2013 Jun 11;7(3):497-512. Epub 2013 Jan 11.

Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC), Laboratory for Pre-Clinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada.

View Article
June 2013
23 Reads
11 PubMed Central Citations(source)
5.33 Impact Factor

Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.

Drugs 2013 Apr;73(5):439-61

Children's Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO, USA.

View Article
April 2013
9 Reads
3 PubMed Central Citations(source)
4.34 Impact Factor

N-acetyl-L-cysteine modulates the metabolism of cis-platin in human plasma in vitro.

Metallomics 2013 Mar;5(3):197-207

Department of Chemistry, University of Calgary, Calgary, AB, Canada.

View Article
March 2013
6 Reads
3 PubMed Central Citations(source)
3.58 Impact Factor

Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.

Pediatr Blood Cancer 2012 Dec 8;59(7):1252-8. Epub 2012 Aug 8.

Kimmel Comprehensive Cancer Center at Johns Hopkins, The Bunting & Blaustein Cancer Research Building, Baltimore, MD 21231, USA.

View Article
December 2012
14 Reads
2 PubMed Central Citations(source)
2.56 Impact Factor

MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL).

Pediatr Blood Cancer 2012 Oct 10;59(4):599-604. Epub 2012 Apr 10.

Department of Genetics, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.

View Article
October 2012
7 Reads
6 PubMed Central Citations(source)
2.56 Impact Factor

Mechanisms of defective erythropoiesis and anemia in pediatric acute lymphoblastic leukemia (ALL).

Ann Hematol 2012 Oct 29;91(10):1513-8. Epub 2012 Apr 29.

Division of Pediatric Hematology, Alberta Children's Hospital, Calgary, Alberta, Canada.

View Article
October 2012
12 Reads
3 PubMed Central Citations(source)
2.63 Impact Factor

Inflammatory biomarkers of pediatric focal cerebral arteriopathy.

Neurology 2012 Sep 22;79(13):1406-8. Epub 2012 Aug 22.

University of Calgary, Calgary, Canada.

View Article
September 2012
8 Reads
3 PubMed Central Citations(source)
8.29 Impact Factor

The effect of sodium thiosulfate on the metabolism of cis-platin in human plasma in vitro.

Metallomics 2012 Aug;4(9):960-7

Department of Chemistry, University of Calgary, Calgary, AB T2N 1N4, Canada.

View Article
August 2012
14 Reads
2 PubMed Central Citations(source)
3.58 Impact Factor

Curcumin blocks Kv11.1 (erg) potassium current and slows proliferation in the infant acute monocytic leukemia cell line THP-1.

Cell Physiol Biochem 2011 16;28(6):1169-80. Epub 2011 Dec 16.

Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.

View Article
April 2012
6 Reads
6 PubMed Central Citations(source)
2.88 Impact Factor

Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents.

J Neurooncol 2012 Mar 5;107(1):111-9. Epub 2011 Oct 5.

Faculty of Kinesiology, University of Calgary, 2500 University Drive NW, Calgary, AB, T2N 1N4, Canada.

View Article
March 2012
11 Reads
1 PubMed Central Citation(source)
3.07 Impact Factor

EphB receptors trigger Akt activation and suppress Fas receptor-induced apoptosis in malignant T lymphocytes.

J Immunol 2011 Dec 28;187(11):5983-94. Epub 2011 Oct 28.

Department of Chemistry and Biochemistry, University of Regina, Regina, Saskatchewan S4S 0A2, Canada.

View Article
December 2011
11 Reads
10 PubMed Central Citations(source)
4.92 Impact Factor

Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition.

Cancer Cell Int 2011 Dec 29;11(1):44. Epub 2011 Dec 29.

Laboratory for Pre-clinical and Drug Discovery Studies, Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) and Division of Pediatric Oncology, Alberta Children's Hospital, 2888 Shaganappi Trail NW, Calgary, T3B 6A8, Canada.

View Article
December 2011
13 Reads
6 PubMed Central Citations(source)
1.99 Impact Factor

Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition.

Leuk Res 2011 Dec 27;35(12):1649-57. Epub 2011 Jul 27.

Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, AB, Canada.

View Article
December 2011
14 Reads
6 PubMed Central Citations(source)
2.35 Impact Factor

Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.

Onco Targets Ther 2011 5;4:149-68. Epub 2011 Sep 5.

Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, AB, Canada.

View Article
November 2011
18 Reads
4 PubMed Central Citations(source)
1.34 Impact Factor

Analysis of multiple growth regulatory proteins using dissociable staining antibody arrays on solid tumor biopsy specimens.

Fetal Pediatr Pathol 2011 28;30(3):177-88. Epub 2011 Feb 28.

Hughes' Children's Cancer Research Centre, Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.

View Article
August 2011
12 Reads
0.40 Impact Factor

Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.

Pediatr Blood Cancer 2011 Mar 28;56(3):353-60. Epub 2010 Nov 28.

Hughes' Children's Cancer Research Centre, University of Calgary, Calgary, Alberta, Canada.

View Article
March 2011
16 Reads
9 PubMed Central Citations(source)
2.56 Impact Factor

Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration.

Breast Cancer Res Treat 2011 Feb 17;126(1):73-83. Epub 2010 Apr 17.

University of Calgary, Calgary, Canada.

View Article
February 2011
10 Reads
4 PubMed Central Citations(source)
3.94 Impact Factor

Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.

Metallomics 2011 Jan 6;3(1):49-55. Epub 2010 Dec 6.

Department of Chemistry, University of Calgary, 2500 University Drive NW, Calgary, AB, T2N 1N4, Canada.

View Article
January 2011
19 Reads
8 PubMed Central Citations(source)
3.58 Impact Factor

Candidate genes and potential targets for therapeutics in Wilms' tumour.

Clin Transl Oncol 2010 Sep;12(9):597-605

Southern Alberta Children's Cancer Program, Alberta Children's Hospital, Calgary, Alberta, Canada.

View Article
September 2010
19 Reads
1.60 Impact Factor

Childhood acute lymphoblastic leukemia (ALL) presenting with severe osteolysis: a model to study leukemia-bone interactions and potential targeted therapeutics.

Pediatr Hematol Oncol 2010 Apr;27(3):212-27

Hughes Children's Cancer Research Centre, University of Calgary, Calgary, Alberta, Canada.

View Article
April 2010
18 Reads
5 PubMed Central Citations(source)
0.96 Impact Factor

Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.

Leuk Lymphoma 2009 Jul;50(7):1174-82

Hughes' Children's Cancer Research Centre, Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.

View Article
July 2009
18 Reads
3 PubMed Central Citations(source)

Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.

J Exp Ther Oncol 2008 ;7(3):183-93

Translational Research Laboratories, Tom Baker Cancer Centre and the Division of Pediatric Oncology Alberta Children's Hospital, Calgary, Alberta, Canada.

View Article
January 2009
12 Reads
1 PubMed Central Citation(source)

Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics.

J Neurooncol 2008 Nov 24;90(2):171-80. Epub 2008 Jul 24.

Translational Research Laboratories, Southern Alberta Children's Cancer Program, The University of Calgary, Calgary, AB, Canada.

View Article
November 2008
13 Reads
8 PubMed Central Citations(source)
3.07 Impact Factor

In human leukemia cells ephrin-B-induced invasive activity is supported by Lck and is associated with reassembling of lipid raft signaling complexes.

Mol Cancer Res 2008 Feb;6(2):291-305

Department of Chemistry and Biochemistry, University of Regina, Regina, SK, Canada.

View Article
February 2008
21 Reads
3 PubMed Central Citations(source)
4.38 Impact Factor

Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts.

Arthritis Res Ther 2006 ;8(4):R94

The Wellesley Toronto Arthritis and Immune Disorder Research Centre, 101 College St, Toronto, Ontario, Canada M5G 1L7.

View Article
February 2007
13 Reads
8 PubMed Central Citations(source)
3.75 Impact Factor

Differentiation of rhabdomyosarcoma cell lines using retinoic acid.

Pediatr Blood Cancer 2006 Nov;47(6):773-84

Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

View Article
November 2006
8 Reads
14 PubMed Central Citations(source)
2.56 Impact Factor

Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.

Cancer Gene Ther 2005 Apr;12(4):397-406

Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

View Article
April 2005
10 Reads
7 PubMed Central Citations(source)
2.42 Impact Factor

Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.

Pediatr Res 2005 Mar 19;57(3):430-7. Epub 2005 Jan 19.

Center for Experimental and Molecular Therapeutics for Childhood Cancers, Southern Alberta Children's Cancer Program, Alberta Children's Hospital, Calgary, Alberta T2T 5C7, Canada.

View Article
March 2005
14 Reads
7 PubMed Central Citations(source)
2.31 Impact Factor

Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome.

Pediatr Hematol Oncol 2004 Apr-May;21(3):209-21

Southern Alberta Children's Cancer Program, Alberta Children's Hospital, 1820, Richmond Road SW, Calgary, Alberta T2T 5C7, Canada.

View Article
October 2004
20 Reads
7 PubMed Central Citations(source)
0.96 Impact Factor

Purine nucleoside phosphorylase deficiency associated with a dysplastic marrow morphology.

Pediatr Res 2004 Mar 7;55(3):472-7. Epub 2004 Jan 7.

Division of Immunology and Allergy, The Hospital for Sick Children, 555 University Ave., Rm. 7279 Elm Wing, Toronto, Ontario, M5G 1X8, Canada.

View Article
March 2004
11 Reads
4 PubMed Central Citations(source)
2.31 Impact Factor

Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth.

Exp Hematol 2003 Aug;31(8):693-701

Southern Alberta Children's Cancer Program, Alberta Children's Hospital, Calgary, Alberta, Canada.

View Article
August 2003
15 Reads
8 PubMed Central Citations(source)
2.48 Impact Factor

Top co-authors

Aarthi Jayanthan
Aarthi Jayanthan

Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory for Pre-Clinical and Drug Discovery Studies

19
Anjali Singh
Anjali Singh

Banaras Hindu University

8
Yibing Ruan
Yibing Ruan

Department of Cancer Epidemiology and Prevention Research

7
Lia Gore
Lia Gore

University of Colorado Cancer Center

5
Melani Sooriyaarachchi
Melani Sooriyaarachchi

University of Calgary

5
Jessica Boklan
Jessica Boklan

University of Arizona

4
Melvin H Freedman
Melvin H Freedman

University of Toronto

4
James A Whitlock
James A Whitlock

Vanderbilt University Medical Center

4
Xueqing Lun
Xueqing Lun

Southern Alberta Cancer Research Institute

4